{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:59:18Z","timestamp":1785329958129,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjcard.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:23:49Z","timestamp":1781076229000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of Guideline-Directed Medical Therapy for Heart Failure and Major Amputation Rates in Patients With Chronic Limb-Threatening Ischemia and Concomitant Heart Failure"],"prefix":"10.1016","volume":"273","author":[{"given":"Patrick A.","family":"Kwaah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Nkongho","family":"Tabot-Ntoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham K.","family":"Carboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun-Ruey","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Elissa Altin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.amjcard.2026.06.002_bib0001","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"Guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.amjcard.2026.06.002_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186081","article-title":"Limb salvage and survival in chronic Limb-threatening ischemia: the need for a fast-track team-based approach","volume":"12","author":"Ventoruzzo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0003","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.avsg.2023.09.077","article-title":"Outcomes of endovascular treatment for critical limb threatening ischemia","volume":"99","author":"Beucler","year":"2024","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0004","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jvs.2025.05.004","article-title":"Conditional survival analysis and risk factors for mortality in patients with chronic limb-threatening ischemia","volume":"82","author":"AbouAyash","year":"2025","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jvs.2025.04.002","article-title":"Influence of heart failure on the clinical outcomes of patients with chronic limb-threatening ischemia after infrainguinal revascularization","volume":"82","author":"Inoue","year":"2025","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehad562","article-title":"Critical limb-threatening ischaemia and microvascular transformation: clinical implications","volume":"45","author":"Tarvainen","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018684","article-title":"Association of heart failure with outcomes among patients with peripheral artery disease: insights from EUCLID","volume":"10","author":"Samsky","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.amjcard.2026.06.002_bib0008","first-page":"1725","article-title":"Impact of congestive heart failure on mid-term outcomes after lower extremity revascularization for peripheral artery disease","volume":"82","author":"Lin","year":"2025","journal-title":"J Vasc Surg"},{"issue":"18","key":"10.1016\/j.amjcard.2026.06.002_bib0009","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.amjmed.2014.06.009","article-title":"Hemoconcentration-guided diuresis in heart failure","volume":"127","author":"Vaduganathan","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0011","unstructured":"Current Opinion in Cardiology. Accessed on October 26, 2025. https:\/\/journals.lww.com\/co-cardiology\/abstract\/2023\/03000\/advances_in_contemporary_medical_management_to.14.aspx"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0012","unstructured":"Real-world data for the life sciences and healthcare. TriNetX. Accessed on June 24, 2025. https:\/\/trinetx.com\/"},{"issue":"8","key":"10.1016\/j.amjcard.2026.06.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 Inhibitor use and risk of clinical events in patients with cancer therapy\u2013Related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/jcdd10120491","article-title":"Association between psychiatric disorders and the incidence of heart failure in women","volume":"10","author":"Antwi-Amoabeng","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0016","doi-asserted-by":"crossref","first-page":"104043","DOI":"10.1016\/j.amjoto.2023.104043","article-title":"Chronic heart failure in patients undergoing major head and neck surgery: a hospital-based study","volume":"45","author":"Alvarez","year":"2024","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.amjcard.2026.06.002_bib0018","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cardfail.2022.05.001","article-title":"Prognostic interplay between COVID-19 and heart failure with reduced ejection fraction","volume":"28","author":"Greene","year":"2022","journal-title":"J Card Fail"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0019","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cardfail.2020.07.015","article-title":"Performance of electronic health record diagnosis codes for ambulatory heart failure encounters","volume":"26","author":"Goyal","year":"2020","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.avsg.2023.08.009","article-title":"The impact of ejection fraction on major adverse limb events after lower extremity revascularization","volume":"98","author":"Jamil","year":"2024","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0023","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.avsg.2023.02.010","article-title":"Risk factors for major amputation in chronic limb-threatening ischemia patients classified as wound, ischemia, and foot infection stage 4 following infrainguinal revascularization","volume":"94","author":"Morisaki","year":"2023","journal-title":"Ann Vasc Surg"},{"issue":"5","key":"10.1016\/j.amjcard.2026.06.002_bib0024","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejvs.2018.06.003","article-title":"Editor\u2019s Choice \u2013 Impact of comorbidity, medication, and gender on amputation rate following revascularisation for chronic limb threatening ischaemia","volume":"56","author":"Fridh","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"24","key":"10.1016\/j.amjcard.2026.06.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023138","article-title":"Association of frailty with treatment selection and long-term outcomes among patients with chronic limb-threatening ischemia","volume":"10","author":"Butala","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.amjcard.2026.06.002_bib0028","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3390\/jcm13092534","article-title":"Endothelial dysfunction in heart failure: what is its role?","volume":"13","author":"Drera","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"Ostergren","year":"2004","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jvs.2024.09.008","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with improved amputation-free survival in chronic limb-threatening ischemia","volume":"81","author":"Elsayed","year":"2025","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.amjcard.2026.06.002_bib0031","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jvs.2017.07.130","article-title":"Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention","volume":"67","author":"Bodewes","year":"2018","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.amjcard.2026.06.002_bib0032","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1358863X15574321","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia","volume":"20","author":"Armstrong","year":"2015","journal-title":"Vasc Med Lond Engl"},{"issue":"3","key":"10.1016\/j.amjcard.2026.06.002_bib0033","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MAJ.0b013e318142b978","article-title":"Angiotensin converting enzyme inhibition enhances collateral artery remodeling in rats with femoral artery occlusion","volume":"335","author":"Ren","year":"2008","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0034","article-title":"Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1\/Sp3-mediated inhibition of notch signaling in male mice","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2011.12.005","article-title":"Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials","volume":"221","author":"Shahin","year":"2012","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0036","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1191\/1358863x03vm502oa","article-title":"The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease","volume":"8","author":"Hirsch","year":"2003","journal-title":"Vasc Med Lond Engl"},{"issue":"10","key":"10.1016\/j.amjcard.2026.06.002_bib0037","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2015.01.033","article-title":"The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure","volume":"65","author":"Braunwald","year":"2015","journal-title":"JACC"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0038","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamacardio.2018.3789","article-title":"Bioactive signaling in next-generation pharmacotherapies for heart failure: a review","volume":"3","author":"Oatmen","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.amjcard.2026.06.002_bib0039","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.amjcard.2026.06.002_bib0040","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0041","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.amjcard.2026.06.002_bib0042","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13647","article-title":"Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers","volume":"21","author":"Yang","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.amjcard.2026.06.002_bib0043","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.amjcard.2026.06.002_bib0044","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"14","key":"10.1016\/j.amjcard.2026.06.002_bib0045","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0046","unstructured":"FDA Adds boxed warning to Canagliflozin for increased amputation risk. Accessed on July 17, 2025. https:\/\/www.jwatch.org\/fw112894\/2017\/05\/17\/fda-adds-boxed-warning-canagliflozin-increased-amputation"},{"issue":"9","key":"10.1016\/j.amjcard.2026.06.002_bib0047","first-page":"22","article-title":"Diabetes drug receives boxed warning for increased risk of leg and foot amputations","volume":"117","author":"Aschenbrenner","year":"2017","journal-title":"AJN Am J Nurs"},{"issue":"24","key":"10.1016\/j.amjcard.2026.06.002_bib0048","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjcard.2026.06.002_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0050","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51\u2009713 individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.amjcard.2026.06.002_bib0051","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjcard.2026.06.002_bib0052","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.amjcard.2026.06.002_bib0053","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehad276","article-title":"Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.amjcard.2026.06.002_bib0054","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0055","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0056","first-page":"22","article-title":"Boxed warning removed from Canagliflozin labeling","volume":"120","author":"Aschenbrenner","year":"2020","journal-title":"AJN Am J Nurs"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0057","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0058","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diab Vasc Dis Res"},{"issue":"15","key":"10.1016\/j.amjcard.2026.06.002_bib0059","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor Dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"6\u20137","key":"10.1016\/j.amjcard.2026.06.002_bib0061","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.acvd.2023.04.002","article-title":"Risk of amputation under diuretics in patients with or at risk of lower extremity arterial disease: a systematic review and meta-analysis","volume":"116","author":"Ba","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0062","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/03007995.2020.1840340","article-title":"Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations","volume":"36","author":"Alshnbari","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"27","key":"10.1016\/j.amjcard.2026.06.002_bib0063","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1097\/MD.0000000000001054","article-title":"Graz critical limb ischemia score: a risk score for critical limb ischemia in peripheral arterial occlusive disease","volume":"94","author":"Gary","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.amjcard.2026.06.002_bib0064","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/CH-120108","article-title":"Reduced amputation rate with isovolemic hemodilution in critical limb ischemia patients","volume":"67","author":"Kim","year":"2017","journal-title":"Clin Hemorheol Microcirc"},{"issue":"5","key":"10.1016\/j.amjcard.2026.06.002_bib0065","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ehf2.12848","article-title":"Compression therapy for leg oedema in patients with heart failure","volume":"7","author":"Urbanek","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"9","key":"10.1016\/j.amjcard.2026.06.002_bib0066","doi-asserted-by":"crossref","first-page":"sfae234","DOI":"10.1093\/ckj\/sfae234","article-title":"Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal doppler ultrasonography","volume":"17","author":"Wallbach","year":"2024","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0067","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.06.002_bib0068","unstructured":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC. Accessed on July 19, 2025. https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2021.12.012"},{"issue":"7","key":"10.1016\/j.amjcard.2026.06.002_bib0069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233161","article-title":"Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction","volume":"15","author":"Loop","year":"2020","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.amjcard.2026.06.002_bib0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"issue":"sup1","key":"10.1016\/j.amjcard.2026.06.002_bib0071","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/03007995.2024.2318002","article-title":"Heart failure management with \u03b2-blockers: can we do better?","volume":"40","author":"de Oliveira","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.amjcard.2026.06.002_bib0072","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amjcard.2026.06.002_bib0073","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1038\/s41598-018-27799-y","article-title":"Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction","volume":"8","author":"Tsujimoto","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.amjcard.2026.06.002_bib0074","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0735-1097(01)01786-7","article-title":"Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation","volume":"39","author":"Hijmering","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.amjcard.2026.06.002_bib0075","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/01.CIR.0000146335.69413.F9","article-title":"Acute beta-blockade increases muscle sympathetic activity and modifies its frequency distribution","volume":"110","author":"Cogliati","year":"2004","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:03:21Z","timestamp":1785326601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926003899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":72,"alternative-id":["S0002914926003899"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.06.002","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Guideline-Directed Medical Therapy for Heart Failure and Major Amputation Rates in Patients With Chronic Limb-Threatening Ischemia and Concomitant Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}